168 related articles for article (PubMed ID: 2055205)
1. Combination of an antiandrogen and a 5 alpha-reductase inhibitor: a further step towards total androgen blockade?
Labrie C; Trudel C; Li S; Martel C; Couêt J; Labrie F
Endocrinology; 1991 Jul; 129(1):566-8. PubMed ID: 2055205
[TBL] [Abstract][Full Text] [Related]
2. Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA.
Martel C; Trudel C; Couet J; Labrie C; Bélanger A; Labrie F
Mol Cell Endocrinol; 1993 Feb; 91(1-2):43-9. PubMed ID: 8472853
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate.
Labrie C; Simard J; Zhao HF; Belanger A; Pelletier G; Labrie F
Endocrinology; 1989 Jun; 124(6):2745-54. PubMed ID: 2524377
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate.
Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB
Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
7. 4-MAPC, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight, DNA, and prostatein concentrations.
Ghusn HF; Shao TC; Klima M; Cunningham GR
J Androl; 1991; 12(5):315-22. PubMed ID: 1765567
[TBL] [Abstract][Full Text] [Related]
8. Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism.
Kelce WR; Lambright CR; Gray LE; Roberts KP
Toxicol Appl Pharmacol; 1997 Jan; 142(1):192-200. PubMed ID: 9007049
[TBL] [Abstract][Full Text] [Related]
9. Sequential androgen blockade: a biological study in the inhibition of prostatic growth.
Fleshner NE; Trachtenberg J
J Urol; 1992 Dec; 148(6):1928-31. PubMed ID: 1331549
[TBL] [Abstract][Full Text] [Related]
10. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.
Wenderoth UK; George FW; Wilson JD
Endocrinology; 1983 Aug; 113(2):569-73. PubMed ID: 6872940
[TBL] [Abstract][Full Text] [Related]
11. Comparison of prostate gene expression and tissue weight changes as monitors of antiandrogen activity in GNRH-inhibited rats.
Nellemann C; Lefevre PA; Ashby J
Birth Defects Res B Dev Reprod Toxicol; 2003 Aug; 68(4):344-54. PubMed ID: 14666997
[TBL] [Abstract][Full Text] [Related]
12. Effects of 4-MAPC, a 5 alpha-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate.
Shao TC; Kong A; Cunningham GR
Prostate; 1994 Apr; 24(4):212-20. PubMed ID: 7511803
[TBL] [Abstract][Full Text] [Related]
13. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
14. Effects of flutamide and finasteride on rat testicular descent.
Spencer JR; Torrado T; Sanchez RS; Vaughan ED; Imperato-McGinley J
Endocrinology; 1991 Aug; 129(2):741-8. PubMed ID: 1677329
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
16. Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor.
Brooks JR; Baptista EM; Berman C; Ham EA; Hichens M; Johnston DB; Primka RL; Rasmusson GH; Reynolds GF; Schmitt SM; Arth GE
Endocrinology; 1981 Sep; 109(3):830-6. PubMed ID: 7262023
[No Abstract] [Full Text] [Related]
17. Prostatein C3-mRNA: a sensitive marker of androgen-responsiveness in prostate explant cultures.
Shao TC; Kong A; Young C; Chu WH; Tindall DJ; Cunningham GR
Prostate; 1990; 17(1):41-55. PubMed ID: 2201006
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroid antiandrogen inhibiting effect on testosterone metabolism in rat prostate and liver.
Reznikov A; Korpacheva T
Endocrinol Exp; 1990 Dec; 24(4):437-47. PubMed ID: 2096078
[TBL] [Abstract][Full Text] [Related]
19. Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate.
Labrie C; Simard J; Zhao HF; Pelletier G; Labrie F
Mol Cell Endocrinol; 1990 Jan; 68(2-3):169-79. PubMed ID: 2138099
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent effects of prolactin on the different lobes of the immature rat prostate.
Reiter E; Lardinois S; Klug M; Sente B; Hennuy B; Bruyninx M; Closset J; Hennen G
Mol Cell Endocrinol; 1995 Jul; 112(1):113-22. PubMed ID: 7589778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
